search
Back to results

A Study to Evaluate the Tolerance, Efficacy and Pharmacokinetics of TQB3454 Tablets

Primary Purpose

Advanced Solid Tumor or Hematologic Tumor

Status
Recruiting
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
TQB3454
Sponsored by
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Advanced Solid Tumor or Hematologic Tumor

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

- 1. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1; Life expectancy ≥12 weeks.

2. Advanced solid tumors or hematological malignancy. 3. Adequate laboratory indicators. 4. No pregnant or breastfeeding women, and a negative pregnancy test. 5. Understood and Signed an informed consent form.

Exclusion Criteria:

  • 1. Has central nervous system metastasis or system leukemia. 2.Previous anti-tumor treatment:

    1. Has received IDH1 mutation inhibitor.
    2. Has received systemic anti-tumor therapy or radiotherapy within 14 days before the first dose.
    3. Has received oral targeted drugs, less than 5 drug half-lives from first dose.
    4. The related toxicity of previous anti-tumor therapy has not recovered to CTCAE ≤ grade 2, except for hair loss.

      3.Complicated disease and medical history:

    1. Active hepatitis B or hepatitis C.
    2. Abnormal kidney.
    3. Abnormal cardiovascular and cerebrovascular.
    4. Abnormal gastrointestinal.
    5. Has medical history of immunodeficiency.
    6. Has bleeding (hemoptysis), coagulopathy, or been using warfarin, aspirin, and other antiplatelet agglutination drugs.
    7. Has uncontrollable systemic bacterial, fungal or viral active infections.
    8. Has medical history of idiopathic pulmonary fibrosis,or tissue pneumonia.
    9. Has allergic constitution or previous severe allergy; or known allergy to ingredients of study drug.
    10. Has neurological or mental disorders.
    11. Has a history of drug abuse or drug addict.
    12. Has received major surgery, open biopsy, or obvious traumatic injury within 4 weeks before the first dose.
    13. According to the judgement of the researchers, there are other factors that subjects are not suitable for the study.

      4. Has participated in other clinical trials within 30 days before participating in this trial.

      5. Female patients during pregnancy or lactation. 6. According to the judgement of the researchers, there are other factors that subjects are not suitable for the study.

      7. criteria for solid tumors:

    1. Has any signs of bleeding constitution.
    2. Has any CTCAE ≥ grade 3 bleeding or bleeding event,within 4 weeks before the first dose.
    3. Has unhealed wounds, fractures, active ulcers of the stomach and duodenum, ulcerative colitis and other digestive tract diseases.
    4. Imaging (CT or MRI) shows that the tumor has invaded the circumference of important blood vessels.
    5. Has uncontrollable pleural effusion, pericardial effusion or ascites that still need repeated drainage.

criteria for blood tumor:

a) Has severe life-threatening leukemia complications.

Sites / Locations

  • Beijing Cancer HospitalRecruiting
  • The Affiliated Hosptial of Xuzhou Medical UniversityRecruiting
  • Tianjing Medical University Cancer Institute&HospitalRecruiting
  • Hematology Hospital of Chinese Academy of Medical SciencesRecruiting
  • The First Affiliated Hosptial Zhejiang University School of MedicalRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

TQB3454 tablets

Arm Description

TQB3454 tablets administered orally once. Then TQB3454 tablets administered orally, once daily in 28-day cycle after 7 days of first administration.

Outcomes

Primary Outcome Measures

Maximum tolerated dose (MTD)
MTD was defined as the dose in which more than 2 of up to 6 patients developed a DLT.

Secondary Outcome Measures

Cmax
Cmax is the maximum plasma concentration of TQB3454 or metabolite(s).
Tmax
To characterize the pharmacokinetics of TQB3454 by assessment of time to reach maximum plasma concentration.
AUC0-t
To characterize the pharmacokinetics of TQB3454 by assessment of area under the plasma concentration time curve from zero to infinity.
Objective response rate (ORR)
Percentage of participants achieving complete response (CR) and partial response (PR).
Progression-free survival (PFS)
PFS defined as the time from first dose to the first documented progressive disease (PD) or death from any cause.
2-hydroxyglutaric acid
Correlation between 2-hydroxyglutaric acid and efficacy

Full Information

First Posted
July 19, 2020
Last Updated
January 6, 2022
Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT04481607
Brief Title
A Study to Evaluate the Tolerance, Efficacy and Pharmacokinetics of TQB3454 Tablets
Official Title
A Phase I, Open-label, Dose Escalation and Expansion Study to Evaluate the Tolerance, Efficacy and Pharmacokinetics of TQB3454 Tablets
Study Type
Interventional

2. Study Status

Record Verification Date
January 2022
Overall Recruitment Status
Recruiting
Study Start Date
August 24, 2020 (Actual)
Primary Completion Date
December 31, 2022 (Anticipated)
Study Completion Date
December 31, 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
This is a open-label, multicenter, phase I study to evaluate tolerance and pharmacokinetics of TQB3454 tablets in subjects with advanced solid tumor or hematologic tumor.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Advanced Solid Tumor or Hematologic Tumor

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
96 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
TQB3454 tablets
Arm Type
Experimental
Arm Description
TQB3454 tablets administered orally once. Then TQB3454 tablets administered orally, once daily in 28-day cycle after 7 days of first administration.
Intervention Type
Drug
Intervention Name(s)
TQB3454
Intervention Description
TQB3454 tablets is a small molecule oral drug.
Primary Outcome Measure Information:
Title
Maximum tolerated dose (MTD)
Description
MTD was defined as the dose in which more than 2 of up to 6 patients developed a DLT.
Time Frame
Baseline up to 28 days
Secondary Outcome Measure Information:
Title
Cmax
Description
Cmax is the maximum plasma concentration of TQB3454 or metabolite(s).
Time Frame
Hour 0(pre-dose), 0.5, 1, 2, 3, 5, 8, 10, 24, 48, 72, 120, 168 hours post-dose on single dose;
Title
Tmax
Description
To characterize the pharmacokinetics of TQB3454 by assessment of time to reach maximum plasma concentration.
Time Frame
Hour 0(pre-dose), 0.5, 1, 2, 3, 5, 8, 10, 24, 48, 72, 120, 168 hours post-dose on single dose;
Title
AUC0-t
Description
To characterize the pharmacokinetics of TQB3454 by assessment of area under the plasma concentration time curve from zero to infinity.
Time Frame
Hour 0(pre-dose), 0.5, 1, 2, 3, 5, 8, 10, 24, 48, 72, 120, 168 hours post-dose on single dose;
Title
Objective response rate (ORR)
Description
Percentage of participants achieving complete response (CR) and partial response (PR).
Time Frame
up to 60 weeks
Title
Progression-free survival (PFS)
Description
PFS defined as the time from first dose to the first documented progressive disease (PD) or death from any cause.
Time Frame
Up to 60 weeks
Title
2-hydroxyglutaric acid
Description
Correlation between 2-hydroxyglutaric acid and efficacy
Time Frame
Hour 0(pre-dose) on single dose; Hour 0(pre-dose) of day1, day8, day15, day28 on multiple dose of first cycle; hour 0(pre-dose) of day15, day28 of second and third cycle; hour 0(pre-dose) of day28 of fourth to eighth cycle.Each cycle is 28 days.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: - 1. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1; Life expectancy ≥12 weeks. 2. Advanced solid tumors or hematological malignancy. 3. Adequate laboratory indicators. 4. No pregnant or breastfeeding women, and a negative pregnancy test. 5. Understood and Signed an informed consent form. Exclusion Criteria: 1. Has central nervous system metastasis or system leukemia. 2.Previous anti-tumor treatment: Has received IDH1 mutation inhibitor. Has received systemic anti-tumor therapy or radiotherapy within 14 days before the first dose. Has received oral targeted drugs, less than 5 drug half-lives from first dose. The related toxicity of previous anti-tumor therapy has not recovered to CTCAE ≤ grade 2, except for hair loss. 3.Complicated disease and medical history: Active hepatitis B or hepatitis C. Abnormal kidney. Abnormal cardiovascular and cerebrovascular. Abnormal gastrointestinal. Has medical history of immunodeficiency. Has bleeding (hemoptysis), coagulopathy, or been using warfarin, aspirin, and other antiplatelet agglutination drugs. Has uncontrollable systemic bacterial, fungal or viral active infections. Has medical history of idiopathic pulmonary fibrosis,or tissue pneumonia. Has allergic constitution or previous severe allergy; or known allergy to ingredients of study drug. Has neurological or mental disorders. Has a history of drug abuse or drug addict. Has received major surgery, open biopsy, or obvious traumatic injury within 4 weeks before the first dose. According to the judgement of the researchers, there are other factors that subjects are not suitable for the study. 4. Has participated in other clinical trials within 30 days before participating in this trial. 5. Female patients during pregnancy or lactation. 6. According to the judgement of the researchers, there are other factors that subjects are not suitable for the study. 7. criteria for solid tumors: Has any signs of bleeding constitution. Has any CTCAE ≥ grade 3 bleeding or bleeding event,within 4 weeks before the first dose. Has unhealed wounds, fractures, active ulcers of the stomach and duodenum, ulcerative colitis and other digestive tract diseases. Imaging (CT or MRI) shows that the tumor has invaded the circumference of important blood vessels. Has uncontrollable pleural effusion, pericardial effusion or ascites that still need repeated drainage. criteria for blood tumor: a) Has severe life-threatening leukemia complications.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Lin Shen, Doctor
Phone
010-88196340
Email
doctorshenlin@sina.cn
Facility Information:
Facility Name
Beijing Cancer Hospital
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100089
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lin Shen, Doctor
Phone
010-88196340
Email
doctorshenlin@sina.cn
First Name & Middle Initial & Last Name & Degree
Lin Shen, Doctor
Facility Name
The Affiliated Hosptial of Xuzhou Medical University
City
Xuzhou
State/Province
Jiangsu
ZIP/Postal Code
221000
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kailin Xu, doctor
Phone
0516-85609999
Email
lihmd@163.com
Facility Name
Tianjing Medical University Cancer Institute&Hospital
City
Tianjin
State/Province
Tianjin
ZIP/Postal Code
300020
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yi Ba, Doctor
Phone
022-23909999
Email
bayi@tjmuch.com
First Name & Middle Initial & Last Name & Degree
Yafei Wang
Phone
022-23909999
Email
Drwang2005@163.com
Facility Name
Hematology Hospital of Chinese Academy of Medical Sciences
City
Tianjin
State/Province
Tianjin
ZIP/Postal Code
300041
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jianxiang Wang, Doctor
Phone
022-23909278
Email
wangjx@ihcams.ac.cn
First Name & Middle Initial & Last Name & Degree
Junyuan Qi, Doctor
Phone
022-23909067
Email
qijy@ihcams.ac.cn
Facility Name
The First Affiliated Hosptial Zhejiang University School of Medical
City
Hangzhou
State/Province
Zhejiang
ZIP/Postal Code
311100
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yi Zheng, Doctor
Phone
0571-87235114
Email
oncologist@zju.edu.cn
First Name & Middle Initial & Last Name & Degree
Jian Liu, Master
Phone
0571-87235114
Email
lindaliu87@zju.edu.cn

12. IPD Sharing Statement

Learn more about this trial

A Study to Evaluate the Tolerance, Efficacy and Pharmacokinetics of TQB3454 Tablets

We'll reach out to this number within 24 hrs